The Anglo-Swedish drugmaker on Friday reported $275 million in income from gross sales of the vaccine, or the equal of $4.04 per dose. AstraZeneca has pledged that it’ll ship the vaccine on a non-profit foundation so long as the pandemic lasts.
The firm stated 30 million doses of the vaccine went to the European Union, 26 million to the UK, 7 million to Gavi, an alliance that secures vaccines for low-income nations, and 5 million to different nations.
The vaccine was developed by researchers at Oxford University, who licensed the know-how to AstraZeneca in an effort to faucet into the corporate’s international manufacturing and distribution capability.
Regulators in a number of jurisdictions, together with the UK, European Union and India have licensed widespread use of the AstraZeneca vaccine, although the US Food and Drug Administration has not.
Concern that the AstraZeneca vaccine could also be linked to uncommon blood clots has led some nations to suggest that it not be utilized in youthful individuals.